{
  "DOI": "10.1038/s41431-023-01380-2",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-023-01380-2",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eHere we report the results of a retrospective germline analysis of 6941 individuals fulfilling the criteria necessary for genetic testing of hereditary breast- and ovarian cancer (HBOC) according to the German S3 or AGO Guidelines. Genetic testing was performed by next-generation sequencing using 123 cancer-associated genes based on the Illumina TruSight® Cancer Sequencing Panel. In 1431 of 6941 cases (20.6%) at least one variant was reported (ACMG/AMP classes 3–5). Of those 56.3% (\u003cjats:italic\u003en\u003c/jats:italic\u003e = 806) were class 4 or 5 and 43.7% (\u003cjats:italic\u003en\u003c/jats:italic\u003e = 625) were a class 3 (VUS). We defined a 14 gene HBOC core gene panel and compared this to a national and different internationally recommended gene panels (German Hereditary Breast and Ovarian Cancer Consortium HBOC Consortium, ClinGen expert Panel, Genomics England PanelsApp) in regard of diagnostic yield, revealing a diagnostic range of pathogenic variants (class 4/5) from 7.8 to 11.6% depending on the panel evaluated. With the 14 HBOC core gene panel having a diagnostic yield of pathogenic variants (class 4/5) of 10.8%. Additionally, 66 (1%) pathogenic variants (ACMG/AMP class 4 or 5) were found in genes outside the 14 HBOC core gene set (secondary findings) that would have been missed with the restriction to the analysis of HBOC genes. Furthermore, we evaluated a workflow for a periodic re-evaluation of variants of uncertain clinical significance (VUS) for the improvement of clinical validity of germline genetic testing.\u003c/jats:p\u003e",
  "alternative-id": [
    "1380"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "11 October 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "18 January 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "26 April 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "15 May 2023"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "The authors declare no competing interests."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Patients provided their informed consent compliant with the respective national ethical standards of Germany. Internal Ethics Committees approved this study."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0003-3798-5977",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Henkel",
      "given": "Jan",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Laner",
      "given": "Andreas",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Locher",
      "given": "Melanie",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wohlfrom",
      "given": "Tobias",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Neitzel",
      "given": "Birgit",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Becker",
      "given": "Kerstin",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Neuhann",
      "given": "Teresa",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Abicht",
      "given": "Angela",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0001-8491-3234",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Steinke-Lange",
      "given": "Verena",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-5172-2818",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Holinski-Feder",
      "given": "Elke",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        5,
        15
      ]
    ],
    "date-time": "2023-05-15T12:14:06Z",
    "timestamp": 1684152846000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        8,
        3
      ]
    ],
    "date-time": "2023-08-03T23:04:06Z",
    "timestamp": 1691103846000
  },
  "indexed": {
    "date-parts": [
      [
        2023,
        11,
        27
      ]
    ],
    "date-time": "2023-11-27T11:51:55Z",
    "timestamp": 1701085915563
  },
  "is-referenced-by-count": 3,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "8",
  "issued": {
    "date-parts": [
      [
        2023,
        5,
        15
      ]
    ]
  },
  "journal-issue": {
    "issue": "8",
    "published-print": {
      "date-parts": [
        [
          2023,
          8
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            5,
            15
          ]
        ],
        "date-time": "2023-05-15T00:00:00Z",
        "timestamp": 1684108800000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            5,
            15
          ]
        ],
        "date-time": "2023-05-15T00:00:00Z",
        "timestamp": 1684108800000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/s41431-023-01380-2.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-023-01380-2",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-023-01380-2.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "925-930",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2023,
        5,
        15
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        5,
        15
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2023,
        8
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3322/caac.21166",
      "doi-asserted-by": "crossref",
      "key": "1380_CR1",
      "unstructured": "Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30."
    },
    {
      "DOI": "10.1186/bcr3493",
      "author": "SA Eccles",
      "doi-asserted-by": "publisher",
      "journal-title": "Breast Cancer Res",
      "key": "1380_CR2",
      "unstructured": "Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15:R92.",
      "volume": "15",
      "year": "2013"
    },
    {
      "DOI": "10.1056/NEJMsr1501341",
      "author": "DF Easton",
      "doi-asserted-by": "publisher",
      "first-page": "2243",
      "journal-title": "N Engl J Med",
      "key": "1380_CR3",
      "unstructured": "Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243–57.",
      "volume": "372",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s10549-017-4181-0",
      "author": "B Crawford",
      "doi-asserted-by": "publisher",
      "first-page": "383",
      "journal-title": "Breast Cancer Res Treat",
      "key": "1380_CR4",
      "unstructured": "Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O, et al. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Breast Cancer Res Treat. 2017;163:383–90.",
      "volume": "163",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ajhg.2018.11.002",
      "author": "N Mavaddat",
      "doi-asserted-by": "publisher",
      "first-page": "21",
      "journal-title": "Am J Hum Genet",
      "key": "1380_CR5",
      "unstructured": "Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104:21–34.",
      "volume": "104",
      "year": "2019"
    },
    {
      "DOI": "10.1002/humu.23017",
      "author": "MR Chandler",
      "doi-asserted-by": "publisher",
      "first-page": "835",
      "journal-title": "Hum Mutat",
      "key": "1380_CR6",
      "unstructured": "Chandler MR, Bilgili EP, Merner ND. A review of whole-exome sequencing efforts toward hereditary breast cancer susceptibility gene discovery. Hum Mutat. 2016;37:835–46.",
      "volume": "37",
      "year": "2016"
    },
    {
      "DOI": "10.1146/annurev.genom.9.081307.164339",
      "author": "C Turnbull",
      "doi-asserted-by": "publisher",
      "first-page": "321",
      "journal-title": "Annu Rev Genomics Hum Genet",
      "key": "1380_CR7",
      "unstructured": "Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet. 2008;9:321–45.",
      "volume": "9",
      "year": "2008"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-05-3546",
      "author": "G Chenevix-Trench",
      "doi-asserted-by": "publisher",
      "first-page": "2019",
      "journal-title": "Cancer Res",
      "key": "1380_CR8",
      "unstructured": "Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006;66:2019–27.",
      "volume": "66",
      "year": "2006"
    },
    {
      "DOI": "10.1111/cge.12315",
      "author": "JM Eggington",
      "doi-asserted-by": "publisher",
      "first-page": "229",
      "journal-title": "Clin Genet",
      "key": "1380_CR9",
      "unstructured": "Eggington JM, Bowles KR, Moyes K, Manley S, Esterling L, Sizemore S, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2014;86:229–37.",
      "volume": "86",
      "year": "2014"
    },
    {
      "DOI": "10.1002/humu.21627",
      "author": "NM Lindor",
      "doi-asserted-by": "publisher",
      "first-page": "8",
      "journal-title": "Hum Mutat",
      "key": "1380_CR10",
      "unstructured": "Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 2012;33:8–21.",
      "volume": "33",
      "year": "2012"
    },
    {
      "DOI": "10.1016/S0140-6736(10)60892-6",
      "author": "A Tutt",
      "doi-asserted-by": "publisher",
      "first-page": "235",
      "journal-title": "Lancet.",
      "key": "1380_CR11",
      "unstructured": "Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1093/annonc/mdv278",
      "author": "DM Eccles",
      "doi-asserted-by": "publisher",
      "first-page": "2057",
      "journal-title": "Ann Oncol",
      "key": "1380_CR12",
      "unstructured": "Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015;26:2057–65.",
      "volume": "26",
      "year": "2015"
    },
    {
      "DOI": "10.1186/s12920-022-01270-4",
      "author": "A Kwong",
      "doi-asserted-by": "publisher",
      "journal-title": "BMC Med Genomics",
      "key": "1380_CR13",
      "unstructured": "Kwong A, Ho CYS, Shin VY, Au CH, Chan TL, Ma ESK. How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer? BMC Med Genomics. 2022;15:122.",
      "volume": "15",
      "year": "2022"
    },
    {
      "DOI": "10.1038/s41436-020-00957-2",
      "author": "C Mighton",
      "doi-asserted-by": "publisher",
      "first-page": "22",
      "journal-title": "Genet Med",
      "key": "1380_CR14",
      "unstructured": "Mighton C, Shickh S, Uleryk E, Pechlivanoglou P, Bombard Y. Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis. Genet Med. 2021;23:22–33.",
      "volume": "23",
      "year": "2021"
    },
    {
      "DOI": "10.1038/gim.2015.30",
      "author": "S Richards",
      "doi-asserted-by": "publisher",
      "first-page": "405",
      "journal-title": "Genet Med",
      "key": "1380_CR15",
      "unstructured": "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41436-018-0361-5",
      "author": "K Lee",
      "doi-asserted-by": "publisher",
      "first-page": "1497",
      "journal-title": "Genet Med",
      "key": "1380_CR16",
      "unstructured": "Lee K, Seifert BA, Shimelis H, Ghosh R, Crowley SB, Carter NJ, et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med. 2019;21:1497–506.",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1913948",
      "author": "L Dorling",
      "doi-asserted-by": "publisher",
      "first-page": "428",
      "journal-title": "N Engl J Med",
      "key": "1380_CR17",
      "unstructured": "Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, et al. Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med. 2021;384:428–39.",
      "volume": "384",
      "year": "2021"
    },
    {
      "DOI": "10.1001/jamaoncol.2015.2690",
      "author": "A Desmond",
      "doi-asserted-by": "publisher",
      "first-page": "943",
      "journal-title": "JAMA Oncol",
      "key": "1380_CR18",
      "unstructured": "Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1:943–51.",
      "volume": "1",
      "year": "2015"
    },
    {
      "DOI": "10.1055/a-1110-0909",
      "author": "B Wappenschmidt",
      "doi-asserted-by": "publisher",
      "first-page": "410",
      "journal-title": "Geburtshilfe Frauenheilkd",
      "key": "1380_CR19",
      "unstructured": "Wappenschmidt B, Hauke J, Faust U, Niederacher D, Wiesmüller L, Schmidt G, et al. Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe Frauenheilkd. 2020;80:410–29.",
      "volume": "80",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s12282-019-00951-w",
      "author": "MK So",
      "doi-asserted-by": "publisher",
      "first-page": "510",
      "journal-title": "Breast Cancer",
      "key": "1380_CR20",
      "unstructured": "So MK, Jeong TD, Lim W, Moon BI, Paik NS, Kim SC, et al. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines. Breast Cancer. 2019;26:510–9.",
      "volume": "26",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s00246-019-02203-2",
      "author": "JS Bennett",
      "doi-asserted-by": "publisher",
      "first-page": "1679",
      "journal-title": "Pediatr Cardiol",
      "key": "1380_CR21",
      "unstructured": "Bennett JS, Bernhardt M, McBride KL, Reshmi SC, Zmuda E, Kertesz NJ, et al. Reclassification of variants of uncertain significance in children with inherited arrhythmia syndromes is predicted by clinical factors. Pediatr Cardiol. 2019;40:1679–87.",
      "volume": "40",
      "year": "2019"
    },
    {
      "DOI": "10.1001/jamapediatrics.2018.2302",
      "author": "JA SoRelle",
      "doi-asserted-by": "publisher",
      "first-page": "e182302",
      "journal-title": "JAMA Pediatr",
      "key": "1380_CR22",
      "unstructured": "SoRelle JA, Thodeson DM, Arnold S, Gotway G, Park JY. Clinical utility of reinterpreting previously reported genomic epilepsy test results for pediatric patients. JAMA Pediatr. 2019;173:e182302.",
      "volume": "173",
      "year": "2019"
    },
    {
      "DOI": "10.18632/oncotarget.26501",
      "author": "TP Slavin",
      "doi-asserted-by": "publisher",
      "first-page": "417",
      "journal-title": "Oncotarget.",
      "key": "1380_CR23",
      "unstructured": "Slavin TP, Manjarrez S, Pritchard CC, Gray S, Weitzel JN. The effects of genomic germline variant reclassification on clinical cancer care. Oncotarget. 2019;10:417–23.",
      "volume": "10",
      "year": "2019"
    },
    {
      "DOI": "10.1200/PO.20.00399",
      "author": "J Chiang",
      "doi-asserted-by": "publisher",
      "first-page": "577",
      "journal-title": "JCO Precis Oncol",
      "key": "1380_CR24",
      "unstructured": "Chiang J, Chia TH, Yuen J, Shaw T, Li ST, Binte Ishak ND, et al. Impact of variant reclassification in cancer predisposition genes on clinical care. JCO Precis Oncol. 2021;5:577–84.",
      "volume": "5",
      "year": "2021"
    },
    {
      "DOI": "10.1007/s00439-017-1779-6",
      "author": "PD Stenson",
      "doi-asserted-by": "publisher",
      "first-page": "665",
      "journal-title": "Hum Genet",
      "key": "1380_CR25",
      "unstructured": "Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136:665–77.",
      "volume": "136",
      "year": "2017"
    },
    {
      "DOI": "10.1093/nar/gkv1222",
      "author": "MJ Landrum",
      "doi-asserted-by": "publisher",
      "first-page": "D862",
      "journal-title": "Nucleic Acids Res",
      "key": "1380_CR26",
      "unstructured": "Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44:D862–8.",
      "volume": "44",
      "year": "2016"
    },
    {
      "DOI": "10.1186/s13073-022-01101-2",
      "author": "O Ceyhan-Birsoy",
      "doi-asserted-by": "publisher",
      "journal-title": "Genome Med",
      "key": "1380_CR27",
      "unstructured": "Ceyhan-Birsoy O, Jayakumaran G, Kemel Y, Misyura M, Aypar U, Jairam S, et al. Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients. Genome Med. 2022;14:92.",
      "volume": "14",
      "year": "2022"
    },
    {
      "DOI": "10.1200/JCO.18.01631",
      "author": "PD Beitsch",
      "doi-asserted-by": "publisher",
      "first-page": "453",
      "journal-title": "J Clin Oncol",
      "key": "1380_CR28",
      "unstructured": "Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37:453–60.",
      "volume": "37",
      "year": "2019"
    },
    {
      "DOI": "10.1001/jamaoncol.2020.6252",
      "author": "NJ Samadder",
      "doi-asserted-by": "publisher",
      "first-page": "230",
      "journal-title": "JAMA Oncol",
      "key": "1380_CR29",
      "unstructured": "Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7:230–7.",
      "volume": "7",
      "year": "2021"
    },
    {
      "DOI": "10.1001/jama.2017.11137",
      "author": "D Mandelker",
      "doi-asserted-by": "publisher",
      "first-page": "825",
      "journal-title": "JAMA.",
      "key": "1380_CR30",
      "unstructured": "Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318:825–35.",
      "volume": "318",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmedgenet-2015-103094",
      "author": "RS van der Post",
      "doi-asserted-by": "publisher",
      "first-page": "361",
      "journal-title": "J Med Genet",
      "key": "1380_CR31",
      "unstructured": "van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361–74.",
      "volume": "52",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41431-020-00758-w",
      "author": "G de Wert",
      "doi-asserted-by": "publisher",
      "first-page": "365",
      "journal-title": "Eur J Hum Genet",
      "key": "1380_CR32",
      "unstructured": "de Wert G, Dondorp W, Clarke A, Dequeker EMC, Cordier C, Deans Z, et al. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2021;29:365–77.",
      "volume": "29",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41431-021-01003-8",
      "author": "LG Biesecker",
      "doi-asserted-by": "publisher",
      "first-page": "256",
      "journal-title": "Eur J Hum Genet",
      "key": "1380_CR33",
      "unstructured": "Biesecker LG. Invited Commentary on “My Research Results: a program to facilitate return of clinically actionable genomic research findings” by Willis et al. Eur J Hum Genet. 2022;30:256–7.",
      "volume": "30",
      "year": "2022"
    },
    {
      "DOI": "10.1002/hast.1011",
      "author": "E Parens",
      "doi-asserted-by": "publisher",
      "first-page": "S2",
      "journal-title": "Hastings Cent Rep",
      "key": "1380_CR34",
      "unstructured": "Parens E, Appelbaum PS. On what we have learned and still need to learn about the psychosocial impacts of genetic testing. Hastings Cent Rep. 2019;49:S2–9.",
      "volume": "49",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.ajhg.2016.06.001",
      "author": "LM Amendola",
      "doi-asserted-by": "publisher",
      "first-page": "247",
      "journal-title": "Am J Hum Genet",
      "key": "1380_CR35",
      "unstructured": "Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet. 2016;99:247.",
      "volume": "99",
      "year": "2016"
    },
    {
      "DOI": "10.1038/gim.2017.14",
      "author": "SM Harrison",
      "doi-asserted-by": "publisher",
      "first-page": "1096",
      "journal-title": "Genet Med",
      "key": "1380_CR36",
      "unstructured": "Harrison SM, Dolinsky JS, Knight Johnson AE, Pesaran T, Azzariti DR, Bale S, et al. Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar. Genet Med. 2017;19:1096–104.",
      "volume": "19",
      "year": "2017"
    }
  ],
  "reference-count": 36,
  "references-count": 36,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-023-01380-2"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "31"
}